SALT LAKE CITY, Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and d ...

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.09%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%.Over the last four quarters, the company has n ...

SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024.Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locke ...

SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results a ...

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.70%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%. Over the last four quarters, the company has ...

SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, ...

SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peerreviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at Christia ...

The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, 2024, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization ranki ...

SALT LAKE CITY, May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another ...

Financial Data and Key Metrics Changes - Net revenue for Q1 2024 was approximately $39,000, a decrease from $100,000 in Q1 2023, attributed to revenue adjustments and optimization of commercial investments [35][38] - Total operating expenses for Q1 2024 were $9.1 million, down 20% from $11.4 million in the same period last year [38] - Net loss for Q1 2024 was $8.1 million, a reduction of 24% from $10.6 million in Q1 2023 [38] - Cash, cash equivalents, and available-for-sale securities as of March 31, 2024, were approximately $85.4 million, an increase of about $5.5 million from $79.9 million at December 31, 2023 [40] Business Line Data and Key Metrics Changes - Research and development expenses were $3.7 million, down 10% from $4.1 million in Q1 2023, primarily due to lower clinical study costs [39] - Selling, general, and administrative expenses for Q1 were $5.4 million, down 26% from $7.3 million in the same period last year [39] Market Data and Key Metrics Changes - The company is focusing on increasing adoption of its tests, particularly in states with high rates of spontaneous premature births, and is engaging with various stakeholders to promote health equity [22][30] Company Strategy and Development Direction - The company aims to position itself for increased test adoption while maintaining a strong balance sheet and cash position [13] - Strategic goals include publishing clinical study results, enhancing R&D for new products, and improving access to products to promote health equity [14][15] - The company is exploring international markets with significant premature birth rates and plans to engage with regulators in those countries [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential impact of upcoming publications of clinical studies on the adoption of the PreTRM test [60] - The company is preparing for a prudent expansion of commercial operations and is mindful of its cash burn rate amid uncertainties in capital markets [41] Other Important Information - The company has validated ambient whole blood collection and begun shipping new kits, which are expected to improve patient access and reduce costs [17][20] - The FDA's recent final LDT rule may create a higher bar for new entrants, which could benefit the company due to its established history and clinical data [25][26] Q&A Session Summary Question: Updates on conversations with KOLs and guideline bodies - Management is engaging with KOLs and regulators and plans to reconvene with guideline-setting bodies closer to the publication of results [45][46] Question: Status of the Time to Birth assay development - The Time to Birth product is being enhanced and data is expected to be available before the end of the year or early next year [50] Question: Clarification on the $5 million investment option - The marketing campaigns announced are cost-effective and do not materially impact the current budget; the $5 million investment will be evaluated based on ROI before deployment [52][54]